Pathnostics products

Use molecular technology to differentiate the virus that causes COVID-19 from Flu and other respiratory viruses. Like other common respiratory tract infections, Influenza and SARS-CoV-2, the virus that causes COVID-19, share similar signs and symptoms. Additionally, co-infection with SARS-CoV-2 and other respiratory viruses, including influenza and RSV, has been described. It is estimated that SARS-CoV-2 co-infections may occur in 20.7% of patients.

More informed treatment decisions in less than one day. Precision diagnostic testing with rapid results for the management of complicated, recurrent or persistent UTIs and elevated risk patients. Guidance® UTI provides personalized results in less than one day from receipt at lab, while culture can take 3-5 days, reducing the need for empiric therapy and supporting antibiotic stewardship initiatives. Results are summarized in an easy- to-read report showing therapy options based on the patient’s individual infection.

Advanced diagnostic testing for patients with suspected acute or chronic prostatitis. Prostatitis is a common urologic diagnosis in men. PCR is more sensitive than traditional culture for the detection of uropathogens.1 Guidance® Prostatitis combines the sensitivity of PCR for organism identification and antibiotic resistance gene detection with a unique technology called Pooled Antibiotics Susceptibility Testing (P-AST™). P-AST™ accounts for interactions in polymicrobial infections that may alter antibiotic resistance. Guidance® Prostatitis is for your patients who you suspect may have acute or chronic prostatitis.

The Guidance Pre Prostate Biopsy Rectal Swab (GPPBRS) test identifies antimicrobials that may be used prophylactically by using our patented Pooled-Antimicrobial Susceptibility Testing technology to determine the presence or absence of resistance genes. When an appropriate antimicrobial is used before and after the prostate biopsy procedure, the risk of infection is reduced. The GPPBRS test is the ONLY test that combines PCR & patented Pooled Antibiotic Susceptibility Testing (P-AST) technology so the Urologist is able to precisely identify and prescribe antibiotics PRIOR to the prostate biopsy procedure thereby significantly reducing the chances of sepsis for the patient.

Prostate biopsies are performed when results from initial tests, like a prostate-specific antigen (PSA) blood test or digital rectal exam, indicate the possibility of prostate cancer. A range of tissue samples are extracted with a needle from the prostate gland and are analyzed under a microscope to identify cancerous cell abnormalities. If cancer is present, it can be localized to the exact region of the prostate from the location of the tissue extraction.

The Pathnostics Respiratory Pathogens Test is a highly specific and sensitive multiplex PCR for the nucleic acid detection of SARS-Cov-2, Influenza A, Influenza B, or respiratory syncytial virus (RSV). Using one nasal swab, our Respiratory Pathogens Test will help providers diagnose patients and give appropriate therapy options.

The Pathnostics COVID-19 PCR Test detects the presence of SARS-CoV-2, the virus that causes COVID-19. The Pathnostics COVID-19 PCR Test is not impacted by the emerging B.1.1.529 (Omicron variant), enabling accurate test results.

This test identifies genetic abnormalities in patients with Barrett’s esophagus and provides an indication of progression requiring additional procedures and targeted management. Utilizing cytology, immunohistochemistry (IHC), and fluorescence in situ hybridization (FISH) testing on brushings from patients with Barrett’s esophagus, patient chromosomal alterations can be distinguished with high sensitivity and specificity with regard to level of dysplasia and adenocarcinoma.

The Gyn Cytology High Risk (HR) test is a powerful tool for stratifying borderline Pap test results, allowing physicians to identify the 10% of patients with borderline abnormal cells. This test can help physicians determine who will progress to cervical cancer and who will not.

The Pap smear is a screening procedure to aid in the detection of cancer and its precursors and should not be used as the sole means to detect cervical cancer. The FDA-approved Aptima® HPV assay is an in vitronucleic acid amplification test that detects several high-risk HPV types. The FDA-approved Aptima Combo 2® assay detects the presence of Chlamydia trachomatis and Neisseria gonorrhoeae.